Acrivon Therapeutics, Inc. Common Stock
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Acrivon Therapeutics, Inc. Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical-stage biopharmaceutical company that develops precision oncology medicines using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to create drug-specific OncoSignature companion diagnostics, which identify patients whose tumors exhibit proteomic signatures predicting sensitivity to its drug candidates independent of genomic alterations; the platform focuses on DNA damage response, cell cycle regulation, and transcriptional regulators in solid tumors including endometrial, ovarian, and bladder cancers. The company's lead product candidate, ACR-368 (prexasertib), is a selective CHK1/2 inhibitor in-licensed from Eli Lilly and Eli Lilly and Company Eli Lilly and Company, currently advancing in a registrational-intent Phase 2b trial for recurrent platinum-resistant endometrial cancer following prior anti-PD-1 therapy, where OncoSignature-positive patients have shown a 35% confirmed overall response rate and 80% tumor shrinkage, with FDA Fast Track designation; ACR-2316, an internally developed selective dual WEE1/PKMYT1 inhibitor designed for superior single-agent activity via strong activation of CDK1, CDK2, and PLK1, is in Phase 1 dose-escalation for advanced solid tumors with a confirmed partial response observed and initial data expected in late 2025; a preclinical cell cycle program targeting an undisclosed node is also progressing toward development candidate nomination. Headquartered in Watertown, Massachusetts, with biomarker discovery operations at its wholly owned subsidiary in Lund, Sweden, Acrivon Therapeutics was founded in 2018 and conducts U.S.-based clinical development while targeting high unmet-need patient populations globally. Recent developments include prioritization of ACR-368 in endometrial cancer with deprioritization of ovarian and bladder arms based on March 2025 data readout showing durable responses exceeding 10 months in relapsed patients, ongoing advancement of ACR-2316 Phase 1 ahead of schedule with preclinical superiority data presented at AACR-NCI-EORTC in October 2025 highlighting differentiated pathway effects, and presentation of AP3 generative phosphoproteomics enhancements including the KaiSR model for expanded kinase-substrate relationships, alongside a cash position of $134.4 million as of September 30, 2025 funding operations into Q2 2027.
Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Acrivon Therapeutics (NASDAQ:ACRV) Trading Up 3.2% – Still a Buy?
Financial Survey: Oasmia Pharmaceutical (OTCMKTS:OASMY) versus Acrivon Therapeutics (NASDAQ:ACRV)
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
Acrivon Therapeutics (NASDAQ:ACRV) CFO Acquires $15,014.40 in Stock
Acrivon Therapeutics (NASDAQ:ACRV) CEO Acquires $82,320.00 in Stock
Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11